Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Total Liabilities (2016 - 2025)

AC Immune (ACIU) has disclosed Total Liabilities for 9 consecutive years, with $135.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Total Liabilities rose 441.85% to $135.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $135.4 million, a 441.85% increase, with the full-year FY2024 number at $135.4 million, up 448.62% from a year prior.
  • Total Liabilities was $135.4 million for Q4 2024 at AC Immune, up from $25.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $135.4 million in Q4 2024 to a low of $17.6 million in Q4 2022.
  • A 5-year average of $47.1 million and a median of $25.7 million in 2020 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 44.95% in 2022, then surged 441.85% in 2024.
  • AC Immune's Total Liabilities stood at $25.7 million in 2020, then increased by 24.18% to $32.0 million in 2021, then plummeted by 44.95% to $17.6 million in 2022, then surged by 42.08% to $25.0 million in 2023, then soared by 441.85% to $135.4 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Total Liabilities are $135.4 million (Q4 2024), $25.0 million (Q4 2023), and $17.6 million (Q4 2022).